近日，百时美施贵宝公布了POETYK PSO 长期扩展试验（POETYK PSO-LTE）的两年结果，证实deucravacitinib治疗成人中重度斑块状银屑病兼具持久的疗效与一致的安全性。 deucravacitinib 的临床疗效在长达两年的研究中持续有效，在长期扩展试验的第 60 周时，观察病例的银屑病 ...

POETYK PSO 长期扩展试验显示，持续接受颂狄多治疗4年后，超七成患者PASI 75（银屑病面积和严重程度指数改善至少75%）持续应答 颂狄多在 POETYK PSO 长期扩展试验开展的第4年期间未观察到新的安全性信号, 安全性特征与既往一致 银屑病是一种常见的慢性、系统性 ...

本研究针对银屑病患者常合并未确诊的银屑病关节炎（PsA）的临床难题，通过POETYK PSO-1/PSO-2试验的汇总分析，评估了TYK2抑制剂 ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced positive results from two pivotal Phase 3 trials evaluating deucravacitinib, an oral, selective tyrosine kinase 2 ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial, consistent with the established Sotyktu safety profile Following five years of continuous Sotyktu treatment, ...

Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Bristol Myers Squibb announced positive results from POETYK PSO-1, the first pivotal phase 3 trial evaluating deucravacitinib (BMS-986165), a novel, oral, selective tyrosine kinase 2 (TYK2) inhibitor, ...

Deucravacitinib was effective and worked faster than placebo through 52 weeks in patients with moderate-to-severe plaque psoriasis. The phase 3 trial, which appears in the Journal of Dermatological ...